Search

Your search keyword '"Bryce, Richard"' showing total 659 results
Start Over Author "Bryce, Richard"
659 results on '"Bryce, Richard"'

1. The need to implement FAIR principles in biomolecular simulations

Author

Amaro, Rommie, Åqvist, Johan, Bahar, Ivet, Battistini, Federica, Bellaiche, Adam, Beltran, Daniel, Biggin, Philip C., Bonomi, Massimiliano, Bowman, Gregory R., Bryce, Richard, Bussi, Giovanni, Carloni, Paolo, Case, David, Cavalli, Andrea, Chang, Chie-En A., Cheatham III, Thomas E., Cheung, Margaret S., Chipot, Cris, Chong, Lillian T., Choudhary, Preeti, Cisneros, Gerardo Andres, Clementi, Cecilia, Collepardo-Guevara, Rosana, Coveney, Peter, Covino, Roberto, Crawford, T. Daniel, Peraro, Matteo Dal, de Groot, Bert, Delemotte, Lucie, De Vivo, Marco, Essex, Jonathan, Fraternali, Franca, Gao, Jiali, Gelpí, Josep Lluís, Gervasio, Francesco Luigi, Gonzalez-Nilo, Fernando Danilo, Grubmüller, Helmut, Guenza, Marina, Guzman, Horacio V., Harris, Sarah, Head-Gordon, Teresa, Hernandez, Rigoberto, Hospital, Adam, Huang, Niu, Huang, Xuhui, Hummer, Gerhard, Iglesias-Fernández, Javier, Jensen, Jan H., Jha, Shantenu, Jiao, Wanting, Jorgensen, William L., Kamerlin, Shina Caroline Lynn, Khalid, Syma, Laughton, Charles, Levitt, Michael, Limongelli, Vittorio, Lindahl, Erik, Lindorff-Larsen, Kresten, Loverde, Sharon, Lundborg, Magnus, Luo, Yun Lyna, Luque, Francisco Javier, Lynch, Charlotte I., MacKerell, Alexander, Magistrato, Alessandra, Marrink, Siewert J., Martin, Hugh, McCammon, J. Andrew, Merz, Kenneth, Moliner, Vicent, Mulholland, Adrian, Murad, Sohail, Naganathan, Athi N., Nangia, Shikha, Noe, Frank, Noy, Agnes, Oláh, Julianna, O'Mara, Megan, Ondrechen, Mary Jo, Onuchic, José N., Onufriev, Alexey, Osuna, Silvia, Panchenko, Anna R., Pantano, Sergio, Parish, Carol, Parrinello, Michele, Perez, Alberto, Perez-Acle, Tomas, Perilla, Juan R., Pettitt, B. Montgomery, Pietropalo, Adriana, Piquemal, Jean-Philip, Poma, Adolfo, Praprotnik, Matej, Ramos, Maria J., Ren, Pengyu, Reuter, Nathalie, Roitberg, Adrian, Rosta, Edina, Rovira, Carme, Roux, Benoit, Röthlisberger, Ursula, Sanbonmatsu, Karissa Y., Schlick, Tamar, Shaytan, Alexey K., Simmerling, Carlos, Smith, Jeremy C., Sugita, Yuji, Świderek, Katarzyna, Taiji, Makoto, Tao, Peng, Tikhonova, Irina G., Tirado-Rives, Julian, Tunón, Inaki, Van Der Kamp, Marc W., Van der Spoel, David, Velankar, Sameer, Voth, Gregory A., Wade, Rebecca, Warshel, Ariel, Welborn, Valerie Vaissier, Wetmore, Stacey, Wong, Chung F., Yang, Lee-Wei, Zacharias, Martin, and Orozco, Modesto

Subjects
Quantitative Biology - Biomolecules
Abstract

This letter illustrates the opinion of the molecular dynamics (MD) community on the need to adopt a new FAIR paradigm for the use of molecular simulations. It highlights the necessity of a collaborative effort to create, establish, and sustain a database that allows findability, accessibility, interoperability, and reusability of molecular dynamics simulation data. Such a development would democratize the field and significantly improve the impact of MD simulations on life science research. This will transform our working paradigm, pushing the field to a new frontier. We invite you to support our initiative at the MDDB community (https://mddbr.eu/community/)

Published
2024

6. Biomarker Analysis of the Phase III NALA Study of Neratinib + Capecitabine versus Lapatinib + Capecitabine in Patients with Previously Treated Metastatic Breast CancerBiomarker Analysis of the Phase III NALA Study in HER2+ MBC

Author

Saura, Cristina, Matito, Judit, Oliveira, Mafalda, Wildiers, Hans, Brufksy, Adam M, Waters, Simon H, Hurvitz, Sara A, Moy, Beverly, Kim, Sung-Bae, Gradishar, William J, Queiroz, Geraldo Silva, Cronemberger, Eduardo, Wallweber, Gerald J, Bebchuk, Judith, Keyvanjah, Kiana, Lalani, Alshad S, Bryce, Richard, Vivancos, Ana, Eli, Lisa D, and Delaloge, Suzette

Subjects
Breast Cancer, Cancer, Detection, screening and diagnosis, 4.2 Evaluation of markers and technologies, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Breast Neoplasms, Capecitabine, Correlation of Data, Female, Humans, Lapatinib, Neoplasm Metastasis, Quinolines, Retreatment, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeNeratinib plus capecitabine (N+C) demonstrated significant progression-free survival (PFS) benefit in NALA (NCT01808573), a randomized phase III trial comparing N+C with lapatinib + capecitabine (L+C) in 621 patients with HER2-positive (HER2+) metastatic breast cancer (MBC) who had received ≥2 prior HER2-directed regimens in the metastatic setting. We evaluated correlations between exploratory biomarkers and PFS.Patients and methodsSomatic mutations were evaluated by next-generation sequencing on primary or metastatic samples. HER2 protein expression was evaluated by central IHC, H-score, and VeraTag/HERmark. p95 expression (truncated HER2) was measured by VeraTag. HRs were estimated using unstratified Cox proportional hazards models.ResultsFour hundred and twenty samples had successful sequencing: 34.0% had PIK3CA mutations and 5.5% had HER2 (ERBB2) mutations. In the combined patient populations, PIK3CA mutations trended toward shorter PFS [wild-type vs. mutant, HR = 0.81; 95% confidence interval (CI), 0.64-1.03], whereas HER2 mutations trended toward longer PFS [HR = 1.69 (95% CI, 0.97-3.29)]. Higher HER2 protein expression was associated with longer PFS [IHC 3+ vs. 2+, HR = 0.67 (0.54-0.82); H-score ≥240 versus

Published
2021

8. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

Author

Hurvitz, Sara A, Saura, Cristina, Oliveira, Mafalda, Trudeau, Maureen E, Moy, Beverly, Delaloge, Suzette, Gradishar, William, Kim, Sung‐Bae, Haley, Barbara, Ryvo, Larisa, Dai, Ming‐Shen, Milovanov, Vladimir, Alarcón, Jesús, Kalmadi, Sujith, Cronemberger, Eduardo, Souza, Cristiano, Landeiro, Luciana, Bose, Ron, Bebchuk, Judith, Kabbinavar, Fairooz, Bryce, Richard, Keyvanjah, Kiana, and Brufsky, Adam M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Breast Cancer, Brain Disorders, Neurosciences, Clinical Trials and Supportive Activities, Clinical Research, Comparative Effectiveness Research, Prevention, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Capecitabine, Central Nervous System, Female, Humans, Quinolines, Receptor, ErbB-2, Treatment Outcome, Central nervous system neoplasms, Lapatinib, Neratinib, Receptor, ErbB-2, Receptor, erbB-2, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundNeratinib has efficacy in central nervous system (CNS) metastases from HER2-positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capecitabine (N + C) versus lapatinib plus capecitabine (L + C).Materials and methodsNALA was a randomized, active-controlled trial in patients who received two or more previous HER2-directed regimens for HER2-positive MBC. Patients with asymptomatic/stable brain metastases (treated or untreated) were eligible. Patients were assigned to N + C (neratinib 240 mg per day, capecitabine 750 mg/m2 twice daily) or L + C (lapatinib 1,250 mg per day, capecitabine 1,000 mg/m2 twice daily) orally. Independently adjudicated progression-free survival (PFS), overall survival (OS), and CNS endpoints were considered.ResultsOf 621 patients enrolled, 101 (16.3%) had known CNS metastases at baseline (N + C, n = 51; L + C, n = 50); 81 had received prior CNS-directed radiotherapy and/or surgery. In the CNS subgroup, mean PFS through 24 months was 7.8 months with N + C versus 5.5 months with L + C (hazard ratio [HR], 0.66; 95% confidence interval [CI], 0.41-1.05), and mean OS through 48 months was 16.4 versus 15.4 months (HR, 0.90; 95% CI, 0.59-1.38). At 12 months, cumulative incidence of interventions for CNS disease was 25.5% for N + C versus 36.0% for L + C, and cumulative incidence of progressive CNS disease was 26.2% versus 41.6%, respectively. In patients with target CNS lesions at baseline (n = 32), confirmed intracranial objective response rates were 26.3% and 15.4%, respectively. No new safety signals were observed.ConclusionThese analyses suggest improved PFS and CNS outcomes with N + C versus L + C in patients with CNS metastases from HER2-positive MBC.Implications for practiceIn a subgroup of patients with central nervous system (CNS) metastases from HER2-positive breast cancer after two or more previous HER2-directed regimens, the combination of neratinib plus capecitabine was associated with improved progression-free survival and CNS outcomes compared with lapatinib plus capecitabine. These findings build on previous phase II and III studies describing efficacy of neratinib in the prevention and treatment of CNS metastases, and support a role for neratinib as a systemic treatment option in the management of patients with HER2-positive brain metastases following antibody-based HER2-directed therapies.

Published
2021

9. Neratinib + capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer and ≥ 2 prior HER2-directed regimens

Author

Moy, Beverly, Oliveira, Mafalda, Saura, Cristina, Gradishar, William, Kim, Sung-Bae, Brufsky, Adam, Hurvitz, Sara A, Ryvo, Larisa, Fagnani, Daniele, Kalmadi, Sujith, Silverman, Paula, Delaloge, Suzette, Alarcon, Jesus, Kwong, Ava, Lee, Keun Seok, Ang, Peter Cher Siang, Ow, Samuel Guan Wei, Chu, Sung-Chao, Bryce, Richard, Keyvanjah, Kiana, Bebchuk, Judith, Zhang, Bo, Oestreicher, Nina, Bose, Ron, and Chan, Nancy

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Capecitabine, Female, Humans, Quality of Life, Quinolines, Receptor, ErbB-2, Neratinib, Metastatic breast cancer, Health-related quality of life, HER2-positive, Receptor, erbB-2, Clinical Sciences, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeTo characterize health-related quality of life (HRQoL) in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) from the NALA phase 3 study.MethodsIn NALA (NCT01808573), patients were randomized 1:1 to neratinib + capecitabine (N + C) or lapatinib + capecitabine (L + C). HRQoL was assessed using seven prespecified scores from the European Organisation for Research and Treatment of Cancer Quality Of Life Questionnaire core module (QLQ-C30) and breast cancer-specific questionnaire (QLQ-BR23) at baseline and every 6 weeks. Descriptive statistics summarized scores over time, mixed models evaluated differences between treatment arms, and Kaplan-Meier methods were used to assess time to deterioration in HRQoL scores of ≥ 10 points.ResultsOf the 621 patients randomized in NALA, patients were included in the HRQoL analysis if they completed baseline and at least one follow-up questionnaire. The summary, global health status, physical functioning, fatigue, constipation, and systemic therapy side effects scores were stable over time with no persistent differences between treatment groups. There were no differences in time to deterioration (TTD) for the QLQ-C30 summary score between treatment arms; the hazard ratio (HR) for N + C vs. L + C was 0.94 (95% CI 0.63-1.40). Only the diarrhea score worsened significantly more in the N + C arm as compared to the L + C arm, and this remained over time (HR for TTD for N + C vs. L + C was 1.71 [95% CI 1.32-2.23]).ConclusionIn NALA, patients treated with N + C maintained their global HRQoL over time, despite a worsening of the diarrhea-related scores. These results may help guide optimal treatment selection for HER2-positive MBC.

Published
2021

10. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Author

Oaknin, Ana, Friedman, Claire F, Roman, Lynda D, D’Souza, Anishka, Brana, Irene, Bidard, François-Clement, Goldman, Jonathan, Alvarez, Edwin A, Boni, Valentina, ElNaggar, Adam C, Passalacqua, Rodolfo, T.M., Khanh, Santin, Alessandro D, Keyvanjah, Kiana, Xu, Feng, Eli, Lisa D, Lalani, Alshad S, Bryce, Richard P, Hyman, David M, Meric-Bernstam, Funda, Solit, David B, and Monk, Bradley J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Administration, Oral, Adult, Diarrhea, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Mutation, Nausea, Neoplasm Recurrence, Local, Progression-Free Survival, Protein Kinase Inhibitors, Quinolines, Receptor, ErbB-2, Response Evaluation Criteria in Solid Tumors, Severity of Illness Index, Uterine Cervical Neoplasms, Cervical cancer, HER2 mutant, Neratinib, Clinical trial, Tyrosine kinase inhibitor, Receptor, erbB-2, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

ObjectiveSomatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active in multiple HER2-mutant cancers. SUMMIT is a phase II basket trial investigating the efficacy and safety of neratinib in solid tumors.MethodsPatients with HER2-mutant, persistent, metastatic/recurrent cervical cancer with disease progression after platinum-based treatment for advanced/recurrent disease received oral neratinib 240 mg/day with mandatory loperamide prophylaxis during cycle 1. The primary endpoint was confirmed objective response rate (ORR). Secondary endpoints included: response duration (DOR); clinical benefit rate (CBR); progression-free survival (PFS); overall survival (OS); safety.ResultsSixteen eligible patients were enrolled; 10 (62.5%) had endocervical adenocarcinoma. The most common HER2 mutation was S310F (63% of patients). Three of 12 RECIST-measurable patients had confirmed partial responses (ORR 25%; 95%CI 5.5-57.2%); 3 had stable disease ≥16 weeks (CBR 50%; 95%CI 21.1-78.9%). DOR for responders were 5.6, 5.9, and 12.3 months. Median PFS was 7.0 months (95%CI 0.7-18.3 months); median OS was 16.8 months (95%CI 4.1-NE months). Diarrhea (75%), nausea (44%), and decreased appetite (38%) were the most common adverse events. One patient (6%) reported grade 3 diarrhea. There were no grade 4 events, and no diarrhea-related treatment discontinuations.ConclusionsNeratinib monotherapy showed evidence of activity in heavily pretreated patients with HER2-mutant cervical cancer, with no new safety signals. Given the few effective options for cervical cancer after platinum-based therapy failure, neratinib warrants further investigation in this molecularly defined patient population.Trial registration numberNCT01953926 (ClinicalTrials.gov), 2013-002872-42 (EudraCT).

Published
2020

11. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Author

Saura, Cristina, Oliveira, Mafalda, Feng, Yin-Hsun, Dai, Ming-Shen, Chen, Shang-Wen, Hurvitz, Sara A, Kim, Sung-Bae, Moy, Beverly, Delaloge, Suzette, Gradishar, William, Masuda, Norikazu, Palacova, Marketa, Trudeau, Maureen E, Mattson, Johanna, Yap, Yoon Sim, Hou, Ming-Feng, De Laurentiis, Michelino, Yeh, Yu-Min, Chang, Hong-Tai, Yau, Thomas, Wildiers, Hans, Haley, Barbara, Fagnani, Daniele, Lu, Yen-Shen, Crown, John, Lin, Johnson, Takahashi, Masato, Takano, Toshimi, Yamaguchi, Miki, Fujii, Takaaki, Yao, Bin, Bebchuk, Judith, Keyvanjah, Kiana, Bryce, Richard, and Brufsky, Adam

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Breast Cancer, Prevention, Clinical Research, Cancer, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Aged, Antineoplastic Combined Chemotherapy Protocols, Brain Neoplasms, Breast Neoplasms, Breast Neoplasms, Male, Capecitabine, Diarrhea, Female, Humans, Kaplan-Meier Estimate, Lapatinib, Male, Middle Aged, Nausea, Progression-Free Survival, Quality of Life, Quinolines, Receptor, ErbB-2, Retreatment, Survival Rate, NALA Investigators, Receptor, erbB-2, Clinical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

PurposeNALA (ClinicalTrials.gov identifier: NCT01808573) is a randomized, active-controlled, phase III trial comparing neratinib, an irreversible pan-HER tyrosine kinase inhibitor (TKI), plus capecitabine (N+C) against lapatinib, a reversible dual TKI, plus capecitabine (L+C) in patients with centrally confirmed HER2-positive, metastatic breast cancer (MBC) with ≥ 2 previous HER2-directed MBC regimens.MethodsPatients, including those with stable, asymptomatic CNS disease, were randomly assigned 1:1 to neratinib (240 mg once every day) plus capecitabine (750 mg/m2 twice a day 14 d/21 d) with loperamide prophylaxis, or to lapatinib (1,250 mg once every day) plus capecitabine (1,000 mg/m2 twice a day 14 d/21 d). Coprimary end points were centrally confirmed progression-free survival (PFS) and overall survival (OS). NALA was considered positive if either primary end point was met (α split between end points). Secondary end points were time to CNS disease intervention, investigator-assessed PFS, objective response rate (ORR), duration of response (DoR), clinical benefit rate, safety, and health-related quality of life (HRQoL).ResultsA total of 621 patients from 28 countries were randomly assigned (N+C, n = 307; L+C, n = 314). Centrally reviewed PFS was improved with N+C (hazard ratio [HR], 0.76; 95% CI, 0.63 to 0.93; stratified log-rank P = .0059). The OS HR was 0.88 (95% CI, 0.72 to 1.07; P = .2098). Fewer interventions for CNS disease occurred with N+C versus L+C (cumulative incidence, 22.8% v 29.2%; P = .043). ORRs were N+C 32.8% (95% CI, 27.1 to 38.9) and L+C 26.7% (95% CI, 21.5 to 32.4; P = .1201); median DoR was 8.5 versus 5.6 months, respectively (HR, 0.50; 95% CI, 0.33 to 0.74; P = .0004). The most common all-grade adverse events were diarrhea (N+C 83% v L+C 66%) and nausea (53% v 42%). Discontinuation rates and HRQoL were similar between groups.ConclusionN+C significantly improved PFS and time to intervention for CNS disease versus L+C. No new N+C safety signals were observed.

Published
2020

13. The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea

Author

Rugo, Hope S, Di Palma, Jack A, Tripathy, Debu, Bryce, Richard, Moran, Susan, Olek, Elizabeth, and Bosserman, Linda

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Foodborne Illness, Digestive Diseases, Prevention, Antineoplastic Agents, Breast Neoplasms, Diagnosis, Differential, Diarrhea, Disease Management, ErbB Receptors, Female, Humans, Incidence, Lung Neoplasms, Male, Post-Exposure Prophylaxis, Protein Kinase Inhibitors, Severity of Illness Index, Time Factors, Cancer, ErbB receptor, Tyrosine kinase inhibitor, Oncology and Carcinogenesis, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeDiarrhea is recognized as a common adverse event associated with tyrosine kinase inhibitors (TKIs), with those targeting the ErbB family of receptors being associated with the highest rate of diarrhea.MethodsThis paper reviews data on the incidence, timing, and duration of diarrhea associated with US Food and Drug Administration-approved ErbB family-targeted TKIs from the published literature, and sets forth recommendations for management.ResultsIn the absence of anti-diarrheal prophylaxis the incidence of any-grade diarrhea varies and typically occurs early during the course of treatment. Although it is difficult to determine if the incidence and severity of diarrhea is related to inhibition of a particular kinase target because of the multi-targeted and overlapping activity of many agents, evidence suggests that second-generation TKIs with broader target profiles (i.e., afatinib, lapatinib, neratinib) result in a higher incidence of diarrhea compared with highly specific first- (erlotinib, gefitinib) or third- (osimertinib) generation agents. The mechanisms responsible for TKI-associated diarrhea are not fully understood and are likely multi-factorial, involving dysregulated ion transport, inflammation, and mucosal injury. Management strategies have been developed-and continue to be refined-to prevent and reduce the severity and duration of TKI-associated diarrhea. For agents associated with more significant symptoms, anti-diarrheal prophylaxis reduces the incidence and severity of diarrhea, and ongoing studies are evaluating specific strategies to further reduce incidence and duration of TKI-associated diarrhea.ConclusionsContinued investigations into risk factors and pharmacogenomic markers for diarrhea may further improve management of this common toxicity.

Published
2019

16. Discovery of Potent Benzothiazole Inhibitors of Oxidoreductase NQO2, a Target for Inflammation and Cancer.

Author

Belgath, Asma A., Emam, Aya M., Taujanskas, Joshua, Bryce, Richard A., Freeman, Sally, and Stratford, Ian J.

Subjects
BENZOTHIAZOLE, DOUBLE bonds, QUINONE, RING formation (Chemistry), CANCER treatment
Abstract

Inhibitors of NQO2 (NRH: quinone oxidoreductase) have potential application in several areas of medicine and pharmacology, including cancer, neurodegeneration (PD and AD), stroke, and diabetes. Here, resveratrol, a known inhibitor of NQO2, was used as the lead by replacing the double bond in resveratrol with a benzothiazole scaffold. Fifty-five benzothiazoles were designed as NQO2 inhibitors and synthesized, comprising five benzothiazole series with 3,5-dimethoxy, 2,4-dimethoxy, 2,5-dimethoxy, 3,4-dimethoxy, and 3,4,5-trimethoxy substituents, the key synthetic step being a Jacobson cyclisation with the appropriate thiobenzamide. All compounds were evaluated in an NQO2 enzyme inhibition assay, with four compounds having IC50 values of <100 nM. The most active (IC50 25 nM) was 6-hydroxy-2-(3',5'-dihydroxyphenyl)benzo[d]thiazole (15), a good mimetic of resveratrol. Three of the 3',4',5'-trimethoxybenzothiazole analogues, with 6-methoxy (40, IC50 51 nM), 6-amino (48, IC50 79 nM), and 6-acetamide (49, IC50 31 nM) substituents, were also potent inhibitors of NQO2. Computational modelling indicated the most active compounds exhibited good shape complementarity and polar interactions with the NQO2 active site. Through the inhibition of NQO2, benzothiazole-based compounds may have the potential to enhance the efficiency of cancer therapies or minimise oxidative damage in neuroinflammation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens

Author

Dai, Ming Shen, Feng, Yin Hsun, Chen, Shang Wen, Masuda, Norikazu, Yau, Thomas, Chen, Shou Tung, Lu, Yen Shen, Yap, Yoon Sim, Ang, Peter C. S., Chu, Sung Chao, Kwong, Ava, Lee, Keun Seok, Ow, Samuel, Kim, Sung Bae, Lin, Johnson, Chung, Hyun Cheol, Ngan, Roger, Kok, Victor C., Rau, Kun Ming, Sangai, Takafumi, Ng, Ting Ying, Tseng, Ling Ming, Bryce, Richard, Bebchuk, Judith, Chen, Mei Chieh, and Hou, Ming Feng

Published
2021
Full Text
View/download PDF

23. Analysis of Glycan Recognition by Concanavalin A Using Absolute Binding Free Energy Calculations

Author

Musleh, Sondos, Alibay, Irfan, Biggin, Philip C., and Bryce, Richard A.

Abstract

Carbohydrates are key biological mediators of molecular recognition and signaling processes. In this case study, we explore the ability of absolute binding free energy (ABFE) calculations to predict the affinities of a set of five related carbohydrate ligands for the lectin protein, concanavalin A, ranging from 27-atom monosaccharides to a 120-atom complex-type N-linked glycan core pentasaccharide. ABFE calculations quantitatively rank and estimate the affinity of the ligands in relation to microcalorimetry, with a mean signed error in the binding free energy of −0.63 ± 0.04 kcal/mol. Consequently, the diminished binding efficiencies of the larger carbohydrate ligands are closely reproduced: the ligand efficiency values from isothermal titration calorimetry for the glycan core pentasaccharide and its constituent trisaccharide and monosaccharide compounds are respectively −0.14, −0.22, and −0.41 kcal/mol per heavy atom. ABFE calculations predict these ligand efficiencies to be −0.14 ± 0.02, −0.24 ± 0.03, and −0.46 ± 0.06 kcal/mol per heavy atom, respectively. Consequently, the ABFE method correctly identifies the high affinity of the key anchoring mannose residue and the negligible contribution to binding of both β-GlcNAc arms of the pentasaccharide. While challenges remain in sampling the conformation and interactions of these polar, flexible, and weakly bound ligands, we nevertheless find that the ABFE method performs well for this lectin system. The approach shows promise as a quantitative tool for predicting and deconvoluting carbohydrate–protein interactions, with potential application to design of therapeutics, vaccines, and diagnostics.

Published
2024
Full Text
View/download PDF

24. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

Author

Chan, Arlene, Moy, Beverly, Mansi, Janine, Ejlertsen, Bent, Holmes, Frankie Ann, Chia, Stephen, Iwata, Hiroji, Gnant, Michael, Loibl, Sibylle, Barrios, Carlos H., Somali, Isil, Smichkoska, Snezhana, Martinez, Noelia, Alonso, Mirta Garcia, Link, John S., Mayer, Ingrid A., Cold, Søren, Murillo, Serafin Morales, Senecal, Francis, Inoue, Kenichi, Ruiz-Borrego, Manuel, Hui, Rina, Denduluri, Neelima, Patt, Debra, Rugo, Hope S., Johnston, Stephen R.D., Bryce, Richard, Zhang, Bo, Xu, Feng, Wong, Alvin, and Martin, Miguel

Published
2021
Full Text
View/download PDF

25. Status and Outlook of CHIP-TRAP: the Central Michigan University High Precision Penning Trap

Author

Redshaw, Matthew, Bryce, Richard A., Hawks, Paul, Gamage, Nadeesha D., Hunt, Curtis, Kandegedara, Rathnayake M. E. B., Ratnayake, Ishara S., and Sharp, Lance

Subjects
Physics - Instrumentation and Detectors, Nuclear Experiment
Abstract

At Central Michigan University we are developing a high-precision Penning trap mass spectrometer (CHIP-TRAP)that will focus on measurements with long-lived radioactive isotopes. CHIP-TRAP will consist of a pair of hyperbolic precision-measurement Penning traps, and a cylindrical capture/filter trap in a 12 T magnetic field. Ions will be produced by external ion sources, including a laser ablation source, and transported to the capture trap at low energies enabling ions of a given m=q ratio to be selected via their time-of-flight. In the capture trap, contaminant ions will be removed with a mass-selective rf dipole excitation and the ion of interest will be transported to the measurement traps. A phase-sensitive image charge detection technique will be used for simultaneous cyclotron frequency measurements on single ions in the two precision traps, resulting in a reduction in statistical uncertainty due to magnetic field fluctuations., Comment: 5 pages, submitted to NIMB (EMIS 2015 Conference Proceedings)

Published
2015
Full Text
View/download PDF

27. Structural determination of oleanane-28,13β-olide and taraxerane-28,14β-olide fluoro­lactonization products from the reaction of oleanolic acid with SelectfluorTM.

Author

Eadsforth, Megan A., Kong, Linghan, Whitehead, George, Vitórica-Yrezábal, Iñigo J., O'Keefe, Raymond T., Bryce, Richard A., and Whiteheada, Roger C.

Subjects
CRYSTAL structure, TRITERPENOIDS, METHANOL, X-rays, ACIDS
Abstract

The X-ray crystal structure data of 12-α-fluoro-3β-hy­droxy­olean-28,13β-olide methanol hemisolvate, 2C30H47FO3·CH3OH, (1), and 12-α-fluoro-3β-hy­droxy­taraxer-28,14β-olide methanol hemisolvate, 2C30H47FO3·CH3OH, (2), are described. The fluoro­lactonization of oleanolic acid using SelectfluorTM yielded a mixture of the six-membered δ-lactone (1) and the unusual seven-membered γ-lactone (2) following a 1,2-shift of methyl C-27 from C-14 to C-13. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. Chronic Cellulitis in the Unhoused: Case Study and Treatment Considerations.

Author

Klamen, Amelia, Bryce, Richard, Martin, Symone, and Benchell Eisman, Eli

Subjects
ANTIBIOTICS, CELLULITIS treatment, CHRONIC disease treatment, CHRONIC disease diagnosis, CELLULITIS, SUBSTANCE abuse, PATIENT education, DIFFERENTIAL diagnosis, ERYTHEMA, EDEMA, HYGIENE, SOCIAL case work, PAIN, DIABETIC foot, DISEASE relapse, ALCOHOLISM, HOUSING, HEALTH care teams, DIABETES
Abstract

This report seeks to discuss sequelae of chronic cellulitis that is commonly treated in the ambulatory setting, as exacerbated by the conditions of living outside. Further we hope to identify etiologic factors that contribute to complication development. Additionally, this article will touch on unique treatment plan considerations for unhoused patients with the intention to educate providers and reduce mortality and morbidity relating to pedal skin and soft tissue infections in this population. This piece examines the case of a 52-year-old man with a history of chronic diseases, substance use disorder, and recurrent cellulitis. We highlight systemic issues in healthcare delivery for unhoused patients, including inadequate discharge planning, limited access to medication, and challenges in shelter placement. The discussion section emphasizes the importance of accurate diagnosis and tailored treatment plans for cellulitis in houseless individuals, the importance of a multidisciplinary approach incorporating social work services, and addressing chronic illnesses, substance use disorder, and housing issues. The report advocates for heightened awareness of bilateral cellulitis in unhoused populations, emphasizing the need for comprehensive, individualized treatment plans. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Structural determination of oleanane-28,13β-olide and taraxerane-28,14β-olide fluorolactonization products from the reaction of oleanolic acid with Selectfluor™.

Author

Eadsforth, Megan A., Kong, Linghan, Whitehead, George, Vitórica-Yrezábal, Iñigo J., O'Keefe, Raymond T., Bryce, Richard A., and Whitehead, Roger C.

Subjects
CRYSTAL structure, TRITERPENOIDS, METHANOL, X-rays, ACIDS
Abstract

The X-ray crystal structure data of 12-α-fluoro-3β-hy­droxy­olean-28,13β-olide methanol hemisolvate, 2C30H47FO3·CH3OH, (1), and 12-α-fluoro-3β-hy­droxy­taraxer-28,14β-olide methanol hemisolvate, 2C30H47FO3·CH3OH, (2), are described. The fluoro­lactonization of oleanolic acid using SelectfluorTM yielded a mixture of the six-membered δ-lactone (1) and the unusual seven-membered γ-lactone (2) following a 1,2-shift of methyl C-27 from C-14 to C-13. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

37. A neural network potential based on pairwise resolved atomic forces and energies.

Author

Kalayan, Jas, Ramzan, Ismaeel, Williams, Christopher D., Bryce, Richard A., and Burton, Neil A.

Subjects
NUCLEAR forces (Physics), NUCLEAR energy, MACHINE learning, POTENTIAL energy, ENERGY conservation, SMALL molecules, FORCE & energy
Abstract

Molecular simulations have become a key tool in molecular and materials design. Machine learning (ML)‐based potential energy functions offer the prospect of simulating complex molecular systems efficiently at quantum chemical accuracy. In previous work, we have introduced the ML‐based PairF‐Net approach to neural network potentials, that adopts a pairwise interatomic scheme to predicting forces within a molecular system. Here, we further develop the PairF‐Net model to intrinsically incorporate energy conservation and couple the model to a molecular mechanical (MM) environment within the OpenMM package. The updated PairF‐Net model yields energy and force predictions and dynamical distributions in good agreement with the rMD17 dataset of ten small organic molecules in the gas‐phase. We further show that these in vacuo ML models of small molecules can be applied to force predictions in aqueous solution via hybrid ML/MM simulations. We present a new benchmark dataset for these ten molecules in solution, obtained from QM/MM simulations, which we denote as rMD17‐aq (https://zenodo.org/records/10048644); and assess the ability of PairF‐Net to reproduce the molecular energy, atomic forces and dynamical distributions of these solution conformations via ML/MM simulations. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Brazilin is a Natural Product Inhibitor of the NLRP3 Inflammasome

Author

McMahon, Emily A, primary, El-Sayed, Sherihan, additional, Green, Jack P, additional, Hoyle, Christopher, additional, Fitzpatrick, Lorna, additional, Jones, Emma, additional, Corrie, Eve, additional, Kelly, Rebecca L, additional, Challinor, Mairi, additional, Freeman, Sally, additional, Bryce, Richard A, additional, Lawrence, Catherine B, additional, Brough, David, additional, and Kasher, Paul R, additional

Published
2023
Full Text
View/download PDF

46. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

Author

Harvey, Vernon, Tomek, Rudolf, Robert, Nicholas J., Gore, Ira, Jr., Smith, John W., II, Masuda, Norikazu, Di Sean Kendall, S., Harker, William Graydon, Petrakova, Katarina, Guerrero Zotano, Angel, Simon, Amparo Ruiz, Konstantinovic, Zora Neskovic, Iannotti, Nicholas O., Tassone, Pierfrancesco, Rodriguez, Gladys I., Jáñez Martinez, Noelia, Crespo Massieu, Carmen, Smickoska, Snezana, Somali, Isil, Yilmaz, Ugur, Alonso, Mirta Garcia, Rosales, Adolfo Murias, Cold, Soeren, Knoop, Ann Soegaard, Patt, Debra, Hellerstedt, Beth A., Morales Murillo, Serafin, Mayer, Ingrid A., Means-Powell, Julie Ann, Hui, Rina, Senecal, Francis M., De Boer, Richard Hendry, Shen, Zhenzhou, Luczak, Adam Andrzej, Chui, Joanna W.Y., Tsang, Janice Wing-hang, Lang, Istvan, Rai, Yoshiaki, Hozumi, Yasuo, Ten Tije, Albert J., Bhandari, Manish, Osborne, Cynthia R.C., Ohtani, Shoichiro, Higaki, Kenji, Watanabe, Kenichi, Taguchi, Kazunori, Takahashi, Masato, Filipovic, Sladjana, Hansen, Vincent L., Rao, Vijayarama Phooshkooru, Gupta, Manish, Petrov, Petar, Coudert, Bruno, Vojnovic, Zeljko, Polya, Zsofia, Miyaki, Toshiko, Yamamoto, Naohito, Brincat, Stephen, Lesniewski-Kmak, Krzysztof, Chmielowska, Ewa, Birhiray, Ruemu E., Citron, Marc L., Papish, Steven William, Berry, William R., Langkjer, Sven Tyge, Garcia Sáenz, José Angel, Arance, Ana Maria, Efrat, Noa, Sarosiek, Tomasz, Grzeda, Lukasz, Manalo, Yvonne, Smith, Julie C., Vaziri, Irfan, Healey, Tabitha, Rahim, Yasmin, Luk, Cynthia, Dingle, Brian, Franco, Sandra, Sorensen, Peter Grundtvig, Anand, Anjana, Khan, Sarah, Fountzilas, George, Aogi, Kenjiro, Shimizu, Satoru, Mikulova, Milada, Spanik, Stanislav, Somer, Robert A., Flynn, Patrick J., Coward, Jermaine, Mainwaring, Paul, Jerusalem, Guy, Segura-Ojezzar, Carine, Levy, Christelle, Delozier, Thierry, Khayat, David, Coleman, Robert E., Rolles, Martin J., Maisano, Robert, Nardi, Mario, Ito, Yoshinori, Yumuk, Perran Fulden, Basaran, Gul, Serdar Turhal, Nazim, Wilkinson, Mary J., Green, Nathan B., Sidrys, Algis P., Hallmeyer, Sigrun, Testori, Douglas J., Sridhar, Srikala, Chang, Jose, Sun, Qiang, Jara-Sanchez, Carlos, Rubio, Xabier, Garrido, Maria Lomas, De La Haba Rodriguez, Juan Rafael, Perello Martorell, Antonia, Avelia Mestre, Antoni, Rifa Ferrer, Julio, del Barco Berron, Sonia, Nagy, Zsuzsanna, Tanaka, Maki, Im, Young-Hyuck, Carroll, Robert R., Dickerson, Laura C., Mace, Joseph R., Rivera, Ragene, Klein, Leonard M., Ruxer, Robert, Wilks, Sharon T., Kotasek, Dusan, Popov, Vasil, Taskova, Violina, Marinova-Venkova, Violetka, Timcheva, Constanta, Desbiens, Christine, Ayoub, Jean-Pierre, Grenier, Debjani, Marschner, Norbert, Tesch, Hans, Lueck, Hans-Joachim, Janssen, Jan, Schwaner, Ingo, Wahlstrom, Stine, Brix, Eva Harder, Vallentin, Susanne, Kristensen, Dan, Andreeva, Anna, Glavicic, Vesna, Calvo Plaza, Isabel, Anton Torres, Antonio, Veyret, Corinne, Bergerat, Jean-Pierre, Bourbouloux, Emmanuelle, Ella, Wendy Ann, Algurafi, Hafiz, Robinson, Anne, Kim, Seung Jin, Taguchi, Tetsuya, Juozaityte, Elona, Madretsma, Stanley, Radema, Sandra, Czerniawska-Meier, Malgorzata, Rogowski, Wojciech, Wagnerova, Maria, Richards, Donald A., Tan-Chiu, Elizabeth, Vasileios, Asskikis, Henderson, Charles Arthur, Holden, Viran Roger, Wang, Xiaojia, Tong, Zhongsheng, Yang, Junlan, Gonzalez, Manuel Enrique, Rezai, Mahdi, Hackmann, John, de Dueñas, Eduardo Martinez, de las Heras, Begoña Bermejo, Dourthe, Louis Marie, Chocteau-Bouju, Dorothee, Bougnoux, Philippe, Kakolyris, Stylianos, Kalofonos, Haralabos, Pectasidis, Dimitrios, Ng, Ting Ying, Pajkos, Gabor, Somogyine, Eva Ezer, Tonini, Giuseppe, Giuffrida, Dario, Takao, Shintaro, Ishitobi, Makoto, Inaji, Hideo, Tokuda, Yutaka, Wozniak, Katarzyna, Lungulescu, Dan, Lu, Yen-Shen, Chang, King-Jen, Hill, Julian, Croot, Christopher Charles, Dekker, Albert, Belman, Neil D., Conde, Miguel, Michaelson, Richard A., Kemmer, Kathleen, Chui, Stephen, Luoh, Shiuh-Wen, Nahum, Kenneth, Greenspan, Andrew R., Nichols, Joni C., Encarnacion, Carlos A., Niederman, Thomas M.J., Lee, Theresa, Alexander, Roland, Gordon, Robert, Tomova, Antoanet, Rauch, Daniel, Popescu, Razvan Andrei, Rojas, Gustavo Adolfo, Vanasek, Jaroslav, Neunhoeffer, Tanja, Barinoff, Jana, Graffunder, Gerd, Wolfgang, Abenhardt, Bojko, Peter, Heinrich, Bernhard, von der Assen, Albert, Antonovic, Bogovic Jurij, Adrian, Lene, Ramos Vazquez, Manuel, Gonzalez Santiago, Santiago, Dieras, Veronique, Bishop, Jill Mercia, Perren, Timothy John, Varthalitis, Ioannis, Mavroudis, Dimitris, Georgoulias, Vassilis, Chow, Louis W.C., Yau, Chung Cheung Thomas, Liang, Raymond Hin-Suen, Pikó, Béla, Wéber, Agnes, Kaufman, Bella, Drumea, Karen, Nuzzo, Francesco, De Matteis, Andrea, Carteni, Giacomo, Tokunaga, Eriko, Ishida, Mayumi, Ohno, Shinji, Sato, Nobuaki, Kuroi, Katsumasa, Nishimura, Reiki, Watanabe, Junichiro, Choi, Yoon Ji, Park, Kyong Hwa, Wojtukiewicz, Marek, Jassem, Jacek, Loman, Niklas, Askoy, Sercan, Altundag, Mustafa Kadri, Saip, Pinar, Ali, Muhammad Amjad, Wade, James Lloyd, III, Chien, Amy Jo, Brandt, Debra, Novik, Yelena, Jani, Chirag, Rice, Robert L., Gaffar, Yousuf A. R, Keaton, Mark R., Bajaj, Rajesh, Kimmick, Gretchen, Campbell, David, Turnquest, Theodore, Lucas, Sideras, Dube, Pierre, Xu, Binghe, Schilling, Joerg, Apel, Klaus, Vestlev, Peter Michael, Jensen, Brita Bjerregaard, Haahr, Vera, Lescure, Alvaro Rodriguez, Grana Suarez, Begona, Saura Manich, Cristina, Jacquin, Jean-Philippe, Samreen, Ahmed, Boiangiu, Ion, Dank, Magdolna, Falci, Cristina, Jirillo, Antonio, Cinieri, Saverio, Ueno, Takayuki, Sato, Fumiaki, Yamashiro, Hiroyasu, Sugie, Tomoharu, Lee, Keun Seok, Ro, Jung Sil, Park, In Hae, Bustam, Anita Zarina, Suszko-Kazarnowicz, Malgorzata, Piktel, Artur, Krzemieniecki, Krzysztof, Iorga, Polizenia Georgeta, Yap, Yoon Sim, Kakalejcik, Marian, Sevinc, Alper, Ozguroglu, Mustafa, Chen, Shin-Cheh, Greenberg, Richard H., Eisemann, Allan Daniel, Droder, Robert, Abbasi, M. Rashid, Vaysburd, Marina, Caldera, Humberto Jose, Haley, Barbara Bacsik, Robin, Erwin, Inhorn, Roger C., Hufnagel, David, Kenyon, Peter D., Spremulli, Ellen, Silverman, Paula, Jain, Sharad, Weigand, Robert, Mebis, Jeroen, Koynova, Tatyana, Lesperance, Bernard, Prausova, Jana, Kohne, Claus-Henning, Schneeweiss, Andreas, Jackisch, Christian, Fuxius, Stefan, Cubedo Cervera, Ricardo, Urruticoechea Ribate, Ander, Pernas Simon, Sonia, Valero Gallego, Jose, Arcusa Lanza, Angels, del Pilar Alvarez, Maria, Florian Gerico, Jesus, Cany, Laurent, Stebbing, Justin, Labudovic, Dejan, Gugic, Damir, Vrbanec, Damir, Roila, Fausto, Barni, Sandro, Bidoli, Paolo, Mukai, Hirofumi, Bermudez, Vanessa, Eniu, Alexandru, Mirtsching, Barry C., Ibrahim, Emad, Trey, Joan, Hergenroeder, Paul Francis, Mahmood, Aftab, Gonzalez, Anneliese, Kaplan, Edward H., Ban, Stacy, Patel, Dhimant, Clowney, Billy, Hoelzer, Karen, Schwartz, Garry H., Salkeni, Mohamed, Abraham, Jame, Narula, Sunil, Jabboury, Khaled, Mocharnuk, Robert Scott, McDonough, Richard H., Sikes, David H., Kawanchi, Ronald H., Schlabach, Larry, McCachren, Samuel Spence, Jr., Cosgriff, Thomas M., Dreisbach, Luke, DeMichele, Angela, Pawl, Lawrence, Lucas, Jennifer, Shinn, Lowell C., Alkhouri, Nabiel, Monga, Manish, Lindquist, Deborah L., Anderson, Thomas C., Khurshid, Humera, Witherby, Sabrina, Erickson, Nicholette, Traynor, Ann, Bose, Ron, Pluard, Timothy J., Jones, Michael C., Prakash, Sucharu, Volterra, Fabio, Capo, Gerardo, Flaherty, Lawrence E., Gartner, Elaina, Baidas, Said, Okazaki, Ian, Nguyen, Bichlien, Rakowski, Thomas, Oliff, Ira, Leach, Joseph W., Anderson, Daniel, Kubiak, Kendra, Tsai, Michaela, Vroman, Philippe, Deleu, Ines, Lybaert, Willem, Borms, Marleen, Couture, Felix, Wilson, Jonathan J., Hunt, Gordon, Holland, David R., Mingrone, Walter, Wang, Shusen, Liu, Donggeng, Jiang, Zefei, Benesova, Vera, Smakal, Martin, Garnolova, Petra, Vesper, Anne-Sophie, Neumann, Monika, Janni, Wolfgang, Liedtke, Cornelia, Fischer, Dorothea, Grischke, Eva-Maria, Seeger, Dietmar, Moebus, Volker, Prechtl, Anita, Carlos Camara Toral, Juan, Sanchez Munoz, Alfonso, Gonzalez Jimenez, Sonia, Cassinello Espinosa, Javier, Cirauqui, Beatriz, Margeli Vila, Mireia, Batista Lopez, Norberto, Chacon Lopez-Muniz, Jose Ignacio, de la Cruz Mora, Miguel Angel, Mailliez, Audrey, Vanlemmens, Laurence, Pouessel, Damien, Espie, Marc, Conibear, John, Roylance, Rebecca, Harnett, Adrian, Geffen, David, Ruggeri, Enzo Maria, Gamucci, Teresa, Van Groeningen, Cees J., Banas, Renata, Alkis, Necati, Hou, Ming-Feng, Krie, Amy K., Vrindavanam, Nandagopal S., Howard, Orion M., Citrin, Dennis, Morginstin, Mark S., Desai, Ajit, Sanchez, Ines J., Nixon, David Allen, Jr., Beatty, Patrick G., Edmiston, Kathryn, McLaughlin, Marilyn, Eneman, Jonathan D., Lynch, Cynthia A., O'Brien, Edward, Call, Justin A., Lanier, Keith S., Conlin, Alison, Brooks, Donald J., McIntyre, Kristi, Saltzman, Marc A., Castine, Michael J., III, Ortega, Gregory L., Choi, Young M., Reynolds, Craig H., Brescia, Frankie Ann, Kramer, Rita, Kohn, Aimee D., Micha, John P., Rhee, Jessica M., Shah, Satish, Riseberg, David A., Patterson, William Kevin, Salmon, Jean-Paul, Andre, Chantal, Bols, Alain, D'hondt, Randal, Luce, Sylvie, Nouwynck, Claire, Pelgrims, Gino, Richard, Vincent, Verschuere, Johan, Geldhof, Kurt, Caspar, Clemens, Luo, Rongcheng, Bednarik, Otakar, Schwedler, Kathrin, Schmidt, Marcus, Neumeister, Romy, Bischoff, Joachim, Rack, Brigitte, Repp, Roland, Fries, Stefan, Adrion, Ralf, Schulz, Volker, Klare, Peter, Danei, Mahmoud, Ossenbuhl, Dirk, Kusche, Jakob Manfred, Griesinger, Frank, Baena Canada, Jose Manuel, Martinez del Prado, Purificacion, Machover, David, Mayeur, Didier, Trufflandier, Nathalie, Delecroix, Valerie, Mousseau, Mireille, Mouret-Reynier, Marie-Ange, Nabholtz, Jean-Marc, Chetiyawardana, Anula D., Papandreou, Christos, Hornyak, Lajos, Faluhelyi, Zsolt, Simo, Erzsebet, Di Palma, Mario, Cognetti, Francesco, Gorzegno, Gabriella, Dogliotti, Luigi, Gridelli, Cesare, Falcone, Alfredo, Soto Parra, Hector, Buscarino, Calogero, Im, Seock-Ah, Sanchez Llamas, Benito, Dercksen, Wouter, Erdkamp, Franciscus, Ruit, Jan B., Braun, Hans, Portielje, Joanneke E.A., Ciltas, Aydin, Buyukberber, Suleyman, Benekli, Mustafa, Zahalsky, Andrew J., Jaslow, Rebecca, Thomas, Gary W., Maini, Archana, Wiznitzer, Israel, Khojasteh, Ali, Francisco Gonzalez, Manuel, Kong, Lynn R., Padmanabhan, Aruna, Conkright, William A., Swain, Sandra M., Faig, Douglas E., Jain, Kirti, Yanagihara, Ronald H., Ottaviano, Yvonne, Delmas, Andrew, Steele, Heather A., Rainey, Gordon K., Harris, Penelope J., Burris, Jason K., Rupard, Erik J., Tan, Esther, Whitworth, Pat W., Bova, Abby R., Anderson, Ian C., Shirinian, Mihran, Tin-u, Caesar, O'Rourke, Timothy J., Roberts, Michael S., Francisco, Michael, Pierson, A. Scott, Byeff, Peter D., Kovach, Peter A., Caton, John R., Jr., Rarick, Mark Urban, Schimidt, William G., Jr., Stopeck, Alison T., Swart, Rachel, Carrillo Flores, Maria Regina, Alemany, Carlos A., Lozada, Brennely, Weinstein, Paul L., Wang, Wei, Porubcin, Michael, Ellison, David M., Geils, George F., Rivera, Edgardo, Charif, Mahmoud, Martin, Miguel, Holmes, Frankie A, Ejlertsen, Bent, Delaloge, Suzette, Moy, Beverly, Iwata, Hiroji, von Minckwitz, Gunter, Chia, Stephen K L, Mansi, Janine, Barrios, Carlos H, Gnant, Michael, Tomašević, Zorica, Denduluri, Neelima, Šeparović, Robert, Gokmen, Erhan, Bashford, Anna, Ruiz Borrego, Manuel, Kim, Sung-Bae, Jakobsen, Erik Hugger, Ciceniene, Audrone, Inoue, Kenichi, Overkamp, Friedrich, Heijns, Joan B, Armstrong, Anne C, Link, John S, Joy, Anil Abraham, Bryce, Richard, Wong, Alvin, Moran, Susan, Yao, Bin, Xu, Feng, Auerbach, Alan, Buyse, Marc, and Chan, Arlene

Published
2017
Full Text
View/download PDF

49. Preparing Distribution Utilities for the Future - Evolving Customer Consumption in Renewable Rich Grids: A Novel Analytical Framework

Author

Nagarajan, Adarsh, primary, Ghosh, Shibani, additional, Duwadi, Kapil, additional, Schwarz, Marty, additional, Bryce, Richard, additional, Chernyakhovskiy, Ilya, additional, Palchak, David, additional, Nalwaya, Jitendra, additional, Dadhich, Mukesh, additional, Agarwal, Prashant, additional, and Sharma, Manu, additional

Published
2021
Full Text
View/download PDF

50. Supplementary Figure S2 from Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Author

Smyth, Lillian M., primary, Piha-Paul, Sarina A., primary, Won, Helen H., primary, Schram, Alison M., primary, Saura, Cristina, primary, Loi, Sherene, primary, Lu, Janice, primary, Shapiro, Geoffrey I., primary, Juric, Dejan, primary, Mayer, Ingrid A., primary, Arteaga, Carlos L., primary, de la Fuente, Macarena I., primary, Brufksy, Adam M., primary, Spanggaard, Iben, primary, Mau-Sørensen, Morten, primary, Arnedos, Monica, primary, Moreno, Victor, primary, Boni, Valentina, primary, Sohn, Joohyuk, primary, Schwartzberg, Lee S., primary, Gonzàlez-Farré, Xavier, primary, Cervantes, Andrés, primary, Bidard, François-Clement, primary, Gorelick, Alexander N., primary, Lanman, Richard B., primary, Nagy, Rebecca J., primary, Ulaner, Gary A., primary, Chandarlapaty, Sarat, primary, Jhaveri, Komal, primary, Gavrila, Elena I., primary, Zimel, Catherine, primary, Selcuklu, S. Duygu, primary, Melcer, Myra, primary, Samoila, Aliaksandra, primary, Cai, Yanyan, primary, Scaltriti, Maurizio, primary, Mann, Grace, primary, Xu, Feng, primary, Eli, Lisa D., primary, Dujka, Melanie, primary, Lalani, Alshad S., primary, Bryce, Richard, primary, Baselga, José, primary, Taylor, Barry S., primary, Solit, David B., primary, Meric-Bernstam, Funda, primary, and Hyman, David M., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results